Global Biosimilars Partnering Deal Terms and Agreements Report/Directory 2022: Disclosed Headlines, Upfronts, Milestones and Royalties by Stage of Development

News provided by

Dec 19, 2022, 10:45 ET

DUBLIN, Dec. 19, 2022 /PRNewswire/ -- The "Global Biosimilars Partnering Terms and Agreements 2010 to 2022" report has been added to ResearchAndMarkets.com's offering.

The Global Biosimilars Partnering Terms and Agreements 2010 to 2022 report provides an understanding and access to 190 biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter biosimilars partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors biosimilars technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual biosimilars deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of biosimilars dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biosimilars dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading biosimilars deals since 2010. Deals are listed by headline value, signed by big pharma, most active biosimilars dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in biosimilars dealmaking with a brief summary followed by a comprehensive listing of biosimilars deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of biosimilars partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of biosimilars partnering deals signed and announced since Jan 2010. The chapter is organized by specific biosimilars technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by biosimilars partnering company A-Z, deal type definitions and biosimilars partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What are the precise rights granted or optioned?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Global Biosimilars Partnering Terms and Agreements 2010 to 2022 includes:

Trends in biosimilars dealmaking in the biopharma industry since 2010
Access to headline, upfront, milestone and royalty data
Access to over 190 biosimilars deal records and contract documents where available
The leading biosimilar deals by value since 2010
Most active biosimilars dealmakers since 2010
The leading biosimilars partnering resources

In Global Biosimilars Partnering Terms and Agreements 2010 to 2022, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy and technology target

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in biosimilars dealmaking
2.1. Introduction
2.2. Biosimilars partnering over the years
2.3. Most active biosimilars dealmakers
2.4. Biosimilars partnering by deal type
2.5. Biosimilars partnering by therapy area
2.6. Deal terms for biosimilars partnering
2.6.1 Biosimilars partnering headline values
2.6.2 Biosimilars deal upfront payments
2.6.3 Biosimilars deal milestone payments
2.6.4 Biosimilars royalty rates

Chapter 3 - Leading biosimilars deals
3.1. Introduction
3.2. Top biosimilars deals by value

Chapter 4 - Most active biosimilars dealmakers
4.1. Introduction
4.2. Most active biosimilars dealmakers
4.3. Most active biosimilars partnering company profiles

Chapter 5 - Biosimilars contracts dealmaking directory
5.1. Introduction
5.2. Biosimilars contracts dealmaking directory

Chapter 6 - Biosimilars dealmaking by technology type

Appendices

Appendix 1 - Biosimilars deals by company A-Z
Appendix 2 - Biosimilars deals by stage of development
Appendix 3 - Biosimilars deals by deal type
Appendix 4 - Biosimilars deals by therapy area
Appendix 5 - Appendix 6 - Recent report titles from

Companies Mentioned

3SBio
180 Life Sciences
Abbvie
Abreos Biosciences
Abzena
Accord Healthcare
Aceno Biotherapeutics
AdAlta
AET Biotech
Aetos Biologics
AffaMed Therapeutics
Agila Specialties
AIT Bioscience
Algorithme Pharma Holdings
Alteogen
Altiora
Alvogen
Alvotech
Amedica
Amgen
Amneal Pharmaceuticals
Arecor
Avid Bioservices
Axantia
Back-A-Line
Bacterin International
Baxalta
Baxter International
BeiGene
Bio-Manguinhos/Fiocruz
Bio-Thera Solutions
Biocnd
Biocon
Bioeq IP
Bio Farma
Biogen
Biooutsource
BiosanaPharma
BioSavita
BioSciencesCorp
Bioton
BioXpress
Boehringer Ingelheim
Bolt Biotherapeutics
Boston Oncology
Bruker
C-Bridge Capital
Catalent
CEA-Leti
Celares
Celerion
Cellectis
Celltrion
Changchun High & New Technology Industries
Chemo Sa Lugano
Chungnam National University
Cipla
CJ Corp
Clinigen
Cobra Biologics
Coherus Biosciences
Compass Biotechnologies
Concord Biosciences
Cook Pharmica
CR Pharma
Daiichi Sankyo
Diabeloop
DM Corporation
Dong-A ST
Dr. Reddy's Laboratories
Dyadic International
EirGenix
EMD Millipore
Enzene Biosciences
Epirus Biopharmaceuticals
Epivax
European Commission
Evercyte
Evotec
Ewopharma
Formosa Pharmaceuticals
Formycon
Fujifilm
Fujifilm Kyowa Kirin Biologics
Fuji Pharma
GC Pharma
Gedeon Richter
GE Healthcare
Genentech
Genhelix Biopharmaceutical
Genor Biopharma
GenScript ProBio
Gerresheimer
Hadasit Medical Research Services and Development
Hanwha Chemical
Helvetic Biopharma
Henlius Biotech
Hikma Pharmaceuticals
Hoffmann La Roche
Horizon 2020
Hospira
Innovent Biologics
Intas Pharmaceuticals
inVentiv Health
Ipca Laboratories
Ipsen
Jacobson Pharma
JAMP Pharma Group
JHL Biotech
Kamada
Karolinska Institute
Kemwell BioPharma
Kymos Pharma Services
Kyowa Hakko Kirin
Laboratorios Liomont
LABORATORIOS SAVAL
Ligacept
Livzon Mabpharm
Lupin
M+W Group
Mab-Venture Biopharma
Mabion
mAbXience
Medicago
Medicure
Medipolis
Meiji Seika
Merck and Co
Merck BioVentures
Merck KGaA
Merck Serono
MGC Diagnostics
Ministry of Health (Brazil)
Mithra Pharmaceuticals
Mitsubishi Chemical
Mochida Pharmaceutical
Momenta Pharmaceuticals
Mundipharma
Mylan Laboratories
Mylan Pharmaceuticals
Nan Fung Group
NanoLock
Natco Pharmaceuticals
National Cancer Institute
National Comprehensive Cancer Network (NCCN)
NCPC GeneTech
Neoletix Biotechnology
NeuClone
Nora Pharma
Novo Nordisk
Ocumension Therapeutics
Oncobiologics
ORF Genetics
Orox Pharmaceuticals
Orygen Biotecnologia
Pall Corporation
Pangen Biotech
Parexel
PBS Biotech
Perfinity Biosciences
Pfenex
Pfizer
Pharmapark
PharmaPraxis
PlantForm
PlantPraxis Biotecnologia
Polpharma
Portal Instruments
PPD
PRA Health Sciences
Premier Inc
Premier Research
Prestige BioPharma
ProBioGen
PT Etana Biotechnologies
Qilu Pharmaceutical
Quanta BioDesign
QuiaPEG Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/5ycg6x

Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets